

Lung Cancer, Non-Small Cell Pathways

Patient Name: _____ **Date of Birth:** _____

Member ID: _____ **Treatment Start Date:** _____

Stage: _____ **Pathology:** _____

ECOG Status: 1 2 3 4 **ICD-10 Code:** _____

Line of Therapy:

- Neoadjuvant/Pre-op
 Adjuvant/Post Op
 1st Line
 2nd Line
 3rd Line
 3rd Line+
 Maintenance

Biomarkers/Attributes: (select all that apply)

ALK Status: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported	MET Amplification: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported
EGFR: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported	RET Gene Rearrangement: <input type="checkbox"/> Absent <input type="checkbox"/> Present <input type="checkbox"/> Not Reported
BRAF: <input type="checkbox"/> V600E Mutation <input type="checkbox"/> V600K Mutation <input type="checkbox"/> Not Reported <input type="checkbox"/> Wild Type	ROS1 Rearrangement: <input type="checkbox"/> Absent <input type="checkbox"/> Present <input type="checkbox"/> Not Reported NTRK 1/2/3 Gene Fusion: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported
PD-L1: <input type="checkbox"/> 1-49% <input type="checkbox"/> ≥50% <input type="checkbox"/> Negative <input type="checkbox"/> Not Reported	Microsatellite Instability: <input type="checkbox"/> dMMR/MSI-H <input type="checkbox"/> MSI-L <input type="checkbox"/> Not Reported T790 Amplification: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported
KRAS: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported	

Neoadjuvant/Adjuvant

Nonsquamous

- Cisplatin + Vinorelbine
- Cisplatin + Pemetrexed +/- concurrent radiation therapy (RT)
- Carboplatin + Paclitaxel +/- concurrent radiation therapy (RT)
- Cisplatin + Etoposide + concurrent radiation therapy (RT)
- Osimertinib (in completely resected stage IB -IIIA EGFR (exon 19del, L858R) directly following completion of adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy))

Squamous

- Cisplatin + Vinorelbine
- Carboplatin + Paclitaxel +/- concurrent radiation therapy (RT)
- Cisplatin + Etoposide + concurrent radiation therapy (RT)
- Osimertinib (in completely resected stage IB -IIIA EGFR (exon 19del, L858R) directly following completion of adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy))

Adjuvant stage III unresectable, no progression, and PS 0-1

- Durvalumab

Advanced/Metastatic

EGFR exon 19 deletion, L858R, S7681, L861Q, and/or G719X Mutation Positive | First and Subsequent Lines of Therapy

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.



- Dacomitinib
- Osimertinib

ALK rearrangement positive | First and Subsequent Line of Therapy

- Alectinib
- Brigatinib

EGFR, ALK, RET Wild type | Nonsquamous | First Line of Therapy

- Pembrolizumab single agents (PD-L1 \geq 50% only)
- Atezolizumab (PD-L1 \geq 50% only)
- Cemiplimab-rwlc (PD-L1 \geq 50% only)
- Carboplatin/Cisplatin + Pemetrexed + Pembrolizumab (PD-L1: <1%, 1-49%, and \geq 50%)

EGFR, ALK, RET Wild type | Nonsquamous | Maintenance

- Pemetrexed
- Pembrolizumab
- Pembrolizumab + Pemetrexed

EGFR, ALK, RET Wild type | Nonsquamous | Second and Subsequent Lines of Therapy

- Docetaxel
- Pemetrexed

EGFR, ALK, RET Wild type | Squamous | First Line of Therapy

- Pembrolizumab single agents (PD-L1 \geq 50% only)
- Atezolizumab (PD-L1 \geq 50% only)
- Cemiplimab-rwlc (PD-L1 \geq 50% only)
- Carboplatin + Paclitaxel + Pembrolizumab (PD-L1: <1%, 1-49%, and \geq 50%)

EGFR, ALK, RET Wild type | Squamous | Maintenance

- Pembrolizumab

EGFR, ALK, RET Wild type | Squamous | Second and Subsequent Lines of Therapy

- Docetaxel

References:

Winton, T., Livingston, R., Johnson, D., et al. (2005, June 23). Vinorelbine Plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/15972865

Douillard, J.-Y., Rosell, R., De Lena, M., et al. (September 2006). Adjuvant Vinorelbine Plus Cisplatin Versus Observation in Patients With Completely Resected Stage IB-III A Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/16945766

Arriagada, R., Bergman, B., Dunant, A., et al. (2004, Jan. 22). Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/14736927

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Sandler, A.B., Nemunaitis, J., Denham, C., et al. (January 2000). Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/10623702

Fossella, F., Pereira, J.R., von Pawel, J., et al. (2003, Aug. 15). Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group. Retrieved from ncbi.nlm.nih.gov/pubmed/?term=12837811

Kreuter, M., Vansteenkiste, J., Fischer, J.R., et al. (April 2013). Randomized Phase 2 Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy With Cisplatin and Pemetrexed Versus Cisplatin and Vinorelbine: The TREAT Study. Retrieved from ncbi.nlm.nih.gov/pubmed/23161898

Zhang, L., Ou, W., Liu, Q., et al. (January 2014). Pemetrexed Plus Carboplatin as Adjuvant Chemotherapy in Patients With Curative Resected Non-Squamous Non-Small Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pmc/articles/PMC4704276

Strauss, G.M., Herndon, J.E., Maddaus, M.A., et al. (2008, Nov. 1). Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group and North Central Cancer Treatment Group Study Groups. Retrieved from ncbi.nlm.nih.gov/pubmed/18809614

Usami, N., Yokoi, K., Hasegawa, Y., et al. (December 2010). Phase II Study of Carboplatin and Gemcitabine as Adjuvant Chemotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer: A Report From the Central Japan Lung Study Group, CJLSG 0503 trial. Retrieved from ncbi.nlm.nih.gov/pubmed/20714770

Pignon, J.-P., Tribodet, H., Scagliotti, G.V., et al. (2008, July 20). Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Retrieved from ncbi.nlm.nih.gov/pubmed/18506026

Scagliotti, G., Parikh, P., von Pawel, J., et al. (2008) Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. *J Clin Oncol* 26: 3543–3551

Albain, K.S., Crowley, J.J., Turrisi, A.T., et al. Concurrent Cisplatin, Etoposide and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II study, SWOG 9019. *J Clin Oncol.* 2002; 20: 3454-3460 51

Curran, W.J., Paulus, R., Langer, C.J., et al. Sequential vs. Concurrent Chemoradiation for Stage III NonSmall Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. *J Natl Cancer Inst.* 2011; 103: 1452-1460

Senan, S., Brade, A., Wang, L.H., et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous NSCLC. *J Clin Oncol* 2016; 34: 953-962

Govindan, R., Bogart, J., Stinchcombe, T., et al. Randomized Phase II Study of Pemetrexed, Carboplatin and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable NonSmall Cell Lung Cancer. Cancer and Leukemia Group B Trial 30407. *J Clin Oncol* 2011; 29: 3120-3125

Bradley, J.D., Paulus, R., Komaki, R., et al. Standard-Dose Versus High-Dose Conformal Radiotherapy With Concurrent and Consolidation Carboplatin Plus Paclitaxel With or Without Cetuximab for Patients With Stage IIIA or IIIB NSCLC (RTOG 0617): A Randomized, Two-by-Two Factorial Phase 3 Study. *Lancet Oncol* 2015; 16: 187-199

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Antonia, S.J., Villegas, A., Daniel, D., et al. Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med* 2017; 377: 1919-1929

Antonia, S.J., Villegas, A., Daniel, D., et al. Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC. *N Engl J Med* 2018; 379: 2342-2550

Rosell, R., Carcereny, E., Gervais, R., et al. (March 2012). Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/22285168

Zhou, C., Wu, Y.L., Chen, G., et al. (September 2015). Final Overall Survival Results From a Randomised, Phase III Study of Erlotinib Versus Chemotherapy as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802). Retrieved from ncbi.nlm.nih.gov/pubmed/26141208

Soria, J.-C., Ohe, Y., Vansteenkiste, J., et al. (2018, Jan. 11). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: *NEJM*. Retrieved from nejm.org/doi/full/10.1056/NEJMoa1713137 22. Ramalingam, S.S., Gray, J.E., Ohe, Y., et al. (2019, Sept. 28). Osimertinib vs. Comparator EGFR-TKI as First-Line Treatment for EGFRm Advanced NSCLC (FLAURA): Final Overall Survival Analysis. Retrieved from oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Osimertinib-vs-comparator-EGFR-TKI-as-first-line-treatment-for-EGFRm-advanced-NSCLC-FLAURA-Final-overall-survival-analysis

Mok, T.S., Wu, Y.-L., Thongprasert, S., et al. (2009, Sept. 3). Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. Retrieved from ncbi.nlm.nih.gov/pubmed/19692680

Inoue, A., Kobayashi, K., Maemondo, M., et al. (January 2013). Updated Overall Survival Results From a Randomized Phase III Trial Comparing Gefitinib With Carboplatin-Paclitaxel for Chemo-Naïve Non-Small Cell Lung Cancer With Sensitive EGFR Gene mutations (NEJ002). Retrieved from ncbi.nlm.nih.gov/pubmed/22967997 52

Wu, Y.-L., Cheng, Y., Zhou, X., et al. (November 2017). Dacomitinib Versus Gefitinib as First-Line Treatment for Patients With EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): A Randomised, Open-Label, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/28958502 26. Mok, T.S., Cheng, Y., Zhou, X., et al. (2018, June 4). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Retrieved from ascopubs.org/doi/10.1200/JCO.2018.78.7994

Urata, Y., Katakami, N., Morita, S., et al. (2016, Sept. 20). Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Retrieved from ncbi.nlm.nih.gov/pubmed/27022112

Sequist, L.V., Yang, J.C.-H., Yamamoto, N., et al. (2013, Sept. 20). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Retrieved from ncbi.nlm.nih.gov/pubmed/23816960

Wu, Y.-L., Zhou, C., Hu, C.-P., et al. (February 2014). Afatinib Versus Cisplatin Plus Gemcitabine for First Line Treatment of Asian Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations (LUX-Lung 6): An Open-Label, Randomised Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/24439929

Yang, J.C.-H., Wu, Y.-L., Schuler, M., et al. (February 2015). Afatinib Versus Cisplatin-Based Chemotherapy for EGFR Mutation-Positive Lung Adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of Overall Survival Data From Two Randomised, Phase 3 Trials. Retrieved from ncbi.nlm.nih.gov/pubmed/25589191

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Paz-Ares, L., Tan, E.-H., O'Byrne, K., et al. (2017, Feb. 1). Afatinib Versus Gefitinib in Patients With EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Overall Survival Data From the Phase IIb LUXLung 7 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/28426106

Planchard, D., Boyer, M.J., Lee, J.-S., et al. (2019, April 1). Postprogression Outcomes for Osimertinib Versus Standard-of-Care EGFR-TKI in Patients With Previously Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/30659024

Mok, T.S., Wu, Y.-L., Ahn, M.-J., et al. (2017, May 18). Osimertinib or Platinum — Pemetrexed in EGFR T790M — Positive Lung Cancer: NEJM. Retrieved from nejm.org/doi/full/10.1056/NEJMoa1612674

Nakagawa, K., Garon, E.B., Seto, T., et al. (December 2019). Ramucirumab Plus Erlotinib in Patients With Untreated, EGFR-Mutated, Advanced Non-Small-Cell Lung Cancer (RELAY): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/31591063

Saito, H., Fukuhara, T., Furuya, N., et al. (May 2019). Erlotinib Plus Bevacizumab Versus Erlotinib Alone in Patients With EGFR-Positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/30975627

Peters, S., Camidge, R., Shaw, A.T., et al. (2019, Dec. 26). Alectinib Versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer: NEJM. Retrieved from nejm.org/doi/full/10.1056/NEJMoa1704795

Hida, T., Nokihara, H., Kondo, M., et al. (2017, July 1). Alectinib Versus Crizotinib in Patients With ALK-Positive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Randomised Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/28501140

Camidge, D.R., Kim, H.R., Ahn, M.-J., et al. (2018, Nov. 22). Brigatinib Versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer: NEJM. Retrieved from nejm.org/doi/full/10.1056/NEJMoa1810171

Soria, J.-C., Tan, D.S.W., Chiari, R., et al. (2017, March 4). First-Line Ceritinib Versus Platinum-Based Chemotherapy in Advanced ALK-Rearranged Non-Small-Cell Lung Cancer (ASCEND-4): A Randomised, Open-Label, Phase 3 Study. Retrieved from ncbi.nlm.nih.gov/pubmed/28126333

Solomon, B.J., Mok, T., Kim, D.-W., et al. (2014, Dec. 4). First-Line Crizotinib Versus Chemotherapy in ALK-Positive Lung Cancer: NEJM. Retrieved from nejm.org/doi/full/10.1056/NEJMoa1408440

Solomon, B.J., Besse, B., Bauer, T.M., et al. (December 2018). Lorlatinib in Patients With ALK-Positive Non-Small-Cell Lung Cancer: Results From a Global Phase 2 Study. Retrieved from ncbi.nlm.nih.gov/pubmed/30413378

Shaw, A.T., Gandhi, L., Gadgeel, S., et al. (February 2016). Alectinib in ALK-Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/26708155

Ou, S.-H.I., Ahn, J.S., De Petris, L., et al. (2016, March 1). Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Retrieved from ncbi.nlm.nih.gov/pubmed/26598747

Kim, D.-W., Tiseo, M., Ahn, M.-J., et al. (2017, Aug. 1). Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/28475456

Shaw, A.T., Kim, T.M., Crinò, L. (July 2017). Ceritinib Versus Chemotherapy in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Given Chemotherapy and Crizotinib (ASCEND-5): A Randomised, Controlled, Open-Label, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/28602779

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

- Reck, M., Grosshansdorf, Johnson, B.E., et al. (2016, Nov. 10). Pembrolizumab Versus Chemotherapy for PD-L1 — Positive Non-Small-Cell Lung Cancer: NEJM. Retrieved from [nejm.org/doi/full/10.1056/NEJMoa1606774](https://doi.org/10.1056/NEJMoa1606774)
- Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2019, Jan. 8). Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PDL1 Tumor Proportion Score of 50% or Greater. Retrieved from [ascopubs.org/doi/10.1200/JCO.18.00149](https://doi.org/10.1200/JCO.18.00149)
- Mok, T.S.K., Wu, Y.-L., Kudaba, I., et al. (2019, May 4). Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/30955977](https://pubmed.ncbi.nlm.nih.gov/30955977)
- Paz-Ares, L., Luft, A., Vicente, D., et al. (2018, Nov. 22). Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/30280635](https://pubmed.ncbi.nlm.nih.gov/30280635)
- Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., et al. (2019, Nov. 21). Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/31562796](https://pubmed.ncbi.nlm.nih.gov/31562796)
- Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., et al. (2018, May 31). Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/29658856](https://pubmed.ncbi.nlm.nih.gov/29658856)
- Gadgeel, S.M., Garassino, M.C., Esteban, E., et al. (2019, May 20). KEYNOTE-189: Updated OS and Progression After the Next Line of Therapy (PFS2) With Pembrolizumab (Pembro) Plus Chemo With Pemetrexed and Platinum vs. Placebo Plus Chemo for Metastatic Nonsquamous NSCLC. Retrieved from [ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9013](https://doi.org/10.1200/JCO.2019.37.15_suppl.9013)
- Langer, C.J., Gadgeel, S.M., Borghaei, H., et al. (November 2016). Carboplatin and Pemetrexed With or Without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/27745820](https://pubmed.ncbi.nlm.nih.gov/27745820)
- Borghaei, H., Langer, C.J., Gadgeel, S., et al. (January 2019). 24-Month Overall Survival From KEYNOTE021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/30138764](https://pubmed.ncbi.nlm.nih.gov/30138764)
- Socinski, M.A., Jotte, R.M., Cappuzzo, F., et al. (2018, June 14). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. Retrieved from [ncbi.nlm.nih.gov/pubmed/29863955](https://pubmed.ncbi.nlm.nih.gov/29863955)
- Socinski, M.A., Jotte, R.M., Capuzzo, F., et al. (2019, May 26). IMpower150: Analysis of Efficacy in Patients (pts) With Liver Metastases (mets). Retrieved from [ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9012](https://doi.org/10.1200/JCO.2019.37.15_suppl.9012)
- West, H., McCleod, M., Hussein, M., et al. (July 2019). Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared With Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/31122901](https://pubmed.ncbi.nlm.nih.gov/31122901)
- Sandler, A., Gray, R., Perry, M.C., et al. (2006, Dec. 14). Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/17167137](https://pubmed.ncbi.nlm.nih.gov/17167137)
- Patel, J.D., Socinski, M.A., Garon, E.B., et al. (2013, Dec. 1). PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/24145346](https://pubmed.ncbi.nlm.nih.gov/24145346)

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Ramalingam, S.S., Dahlberg, S.E., Belani, C.P., et al. (2019, Sept. 10). Pemetrexed, Bevacizumab or the Combination as Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOGACRIN 5508. Retrieved from ncbi.nlm.nih.gov/pubmed/31361535

Barlesi, F., Scherpereel, A., Rittmeyer, A., et al. (2013, Aug. 20). Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089). Retrieved from ncbi.nlm.nih.gov/pubmed/23835708

Barlesi, F., Scherpereel, A., Gorbunova, V., et al. (May 2014). Maintenance Bevacizumab-Pemetrexed After First-Line Cisplatin-Pemetrexed-Bevacizumab for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Updated Survival Analysis of the AVAPERL (MO22089) Randomized Phase III Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/24585722 55

Socinski, M.A., Bondarenko, I., Karaseva, N.A., et al. (2012, June 10). Weekly Nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/22547591

Fossella, F., Pereira, J.R., von Pawel, J., et al. (2003, Aug. 15). Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group. Retrieved from ncbi.nlm.nih.gov/pubmed/12837811

Frasci, G., Comella, P., Panza, N., et al. (October 1998). Carboplatin-Oral Etoposide Personalized Dosing in Elderly Non-Small-Cell Lung Cancer Patients. Gruppo Oncologico Cooperativo Sud-Italia. Retrieved from ncbi.nlm.nih.gov/pubmed/9893657

Danson, S., Middleton, M.R., O'Byrne, K.J., et al. (2003, Aug. 1). Phase III Trial of Gemcitabine and Carboplatin Versus Mitomycin, Ifosfamide and Cisplatin or Mitomycin, Vinblastine and Cisplatin in Patients With Advanced Non-Small-Cell Lung Carcinoma. Retrieved from ncbi.nlm.nih.gov/pubmed/12879472

Ohe, Y., Ohashi, Y., Kubota, K., et al. (February 2007). Randomized Phase III Study of Cisplatin Plus Irinotecan Versus Carboplatin Plus Paclitaxel, Cisplatin Plus Gemcitabine, and Cisplatin Plus Vinorelbine for Advanced Non-Small-Cell Lung Cancer: Four-Arm Cooperative Study in Japan. Retrieved from ncbi.nlm.nih.gov/pubmed/17079694

Belani, C.P., Lee, J.S., Socinski, M.A., et al. (July 2005). Randomized Phase III Trial Comparing CisplatinEtoposide to Carboplatin-Paclitaxel in Advanced or Metastatic Non-Small Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/15860487

Schiller, J.H., Harrington, D., Belani, C.P., et al. (2002, Jan. 10). Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/11784875

Zukin, M., Barrios, C.H., Pereira, J.R., et al. (2013, Aug. 10). Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2. Retrieved from ascopubs.org/doi/full/10.1200/JCO.2012.48.1911?rss=1

Scagliotti, G.V., Kortsik, C., Dark, G.G., et al. (2005, Jan. 15). Pemetrexed Combined With Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non-Small-Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/15701857

Cardenal, F., López-Cabrerizo, M.P., Antón, A., et al. (January 1999). Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic NonSmall-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/10458212

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Scagliotti, G.V., Parikh, P., von Pawel, J., et al. (2008, July 20). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage NonSmall-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/18506025](https://pubmed.ncbi.nlm.nih.gov/18506025)

Smit, E.F., van Meerbeeck, J.P.A.M., Lianes, P., et al. (2003, Nov. 1). Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. Retrieved from [ncbi.nlm.nih.gov/pubmed/14581415](https://pubmed.ncbi.nlm.nih.gov/14581415) 56

Pujol, J.-L., Breton, J.-L., Gervais, R., et al. (April 2005). Gemcitabine-Docetaxel Versus CisplatinVinorelbine in Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase III Study Addressing the Case for Cisplatin. Retrieved from [ncbi.nlm.nih.gov/pubmed/15741225](https://pubmed.ncbi.nlm.nih.gov/15741225)

Tan, E.H., Szczesna, A., Krzakowski, M., et al. (August 2005). Randomized Study of Vinorelbine — Gemcitabine Versus Vinorelbine — Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/16022917](https://pubmed.ncbi.nlm.nih.gov/16022917)

Green, M.R., Manikhas, G.M., Orlov, S., et al. (August 2006). Abraxane, a Novel Cremophor-Free, AlbuminBound Particle Form of Paclitaxel for the Treatment of Advanced Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/16740598](https://pubmed.ncbi.nlm.nih.gov/16740598)

Hanna, N., Shepherd, F.A., Fossella, F.V., et al. (2004, May 1). Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. Retrieved from [ncbi.nlm.nih.gov/pubmed/15117980](https://pubmed.ncbi.nlm.nih.gov/15117980)

Zatloukal, P., Kanitz, E., Magyar, P., et al. (December 1998). Gemcitabine in Locally Advanced and Metastatic Non-Small Cell Lung Cancer: The Central European Phase II Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/10048477](https://pubmed.ncbi.nlm.nih.gov/10048477)

Ceresoli, G.L., Gregorc, V., Cordio, S., et al. (May 2004). Phase II Study of Weekly Paclitaxel as SecondLine Therapy in Patients With Advanced Non-Small Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/15084388](https://pubmed.ncbi.nlm.nih.gov/15084388)

Lilenbaum, R.C., Herndon, J.E., List, M.A., et al. (2005, Jan. 1). Single-Agent Versus Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The Cancer and Leukemia Group B (Study 9730). Retrieved from [ncbi.nlm.nih.gov/pubmed/15625373](https://pubmed.ncbi.nlm.nih.gov/15625373)

Rosell, R., Carcereny, E., Gervais, R., et al. (March 2012). Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/22285168](https://pubmed.ncbi.nlm.nih.gov/22285168)

Zhou, C., Wu, Y.L., Chen, G., et al. (September 2015). Final Overall Survival Results From a Randomised, Phase III Study of Erlotinib Versus Chemotherapy as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802). Retrieved from [ncbi.nlm.nih.gov/pubmed/26141208](https://pubmed.ncbi.nlm.nih.gov/26141208)

Soria, J.-C., Ohe, Y., Vansteenkiste, J., et al. (2018, Jan. 11). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: NEJM. Retrieved from [nejm.org/doi/full/10.1056/NEJMoa1713137](https://doi.org/10.1056/NEJMoa1713137)

Ramalingam, S.S., Gray, J.E., Ohe, Y., et al. (2019, Sept. 28). Osimertinib vs. Comparator EGFR-TKI as First-Line Treatment for EGFRm Advanced NSCLC (FLAURA): Final Overall Survival Analysis. Retrieved from oncolpro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Osimertinib-vs-comparator-EGFR-TKI-as-first-line-treatment-for-EGFRm-advanced-NSCLC-FLAURA-Final-overall-survival-analysis

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Mok, T.S., Wu, Y.-L., Thongprasert, S., et al. (2009, Sept. 3). Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. Retrieved from ncbi.nlm.nih.gov/pubmed/19692680

Inoue, A., Kobayashi, K., Maemondo, M., et al. (January 2013). Updated Overall Survival Results From a Randomized Phase III Trial Comparing Gefitinib With Carboplatin-Paclitaxel for Chemo-Naïve Non-Small-Cell Lung Cancer With Sensitive EGFR Gene Mutations (NEJ002). Retrieved from ncbi.nlm.nih.gov/pubmed/22967997

Wu, Y.-L., Cheng, Y., Zhou, X., et al. (November 2017). Dacomitinib Versus Gefitinib as First-Line Treatment for Patients With EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): A Randomised, Open-Label, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/28958502

Mok, T.S., Cheng, Y., Zhou, X., et al. (2018, June 4). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Retrieved from ascopubs.org/doi/10.1200/JCO.2018

7994 90. Urata, Y., Katakami, N., Morita, S., et al. (2016, Sept. 20). Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Retrieved from ncbi.nlm.nih.gov/pubmed/27022112 91. Sequist, L.V., Yang, J.C.-H., Yamamoto, N., et al. (2013, Sept. 20). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Retrieved from ncbi.nlm.nih.gov/pubmed/23816960

Wu, Y.-L., Zhou, C., Hu, C.-P., et al. (February 2014). Afatinib Versus Cisplatin Plus Gemcitabine for First-Line Treatment of Asian Patients With Advanced Non-Small-Cell Lung Cancer Harbouring EGFR Mutations (LUX-Lung 6): An Open-Label, Randomised Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/24439929

Yang, J.C.-H., Wu, Y.-L., Schuler, M., et al. (February 2015). Afatinib Versus Cisplatin-Based Chemotherapy for EGFR Mutation-Positive Lung Adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of Overall Survival Data From Two Randomised, Phase 3 Trials. Retrieved from ncbi.nlm.nih.gov/pubmed/25589191

Paz-Ares, L., Tan, E.-H., O'Byrne, K., et al. (2017, Feb. 1). Afatinib Versus Gefitinib in Patients With EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Overall Survival Data From the Phase IIb LUXLung 7 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/28426106

Planchard, D., Boyer, M.J., Lee, J.-S., et al. (2019, April 1). Post-Progression Outcomes for Osimertinib Versus Standard-of-Care EGFR-TKI in Patients With Previously Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/30659024

Mok, T.S., Wu, Y.-L., Ahn, M.-J., et al. (2017, May 18). Osimertinib or Platinum — Pemetrexed in EGFR T790M — Positive Lung Cancer: NEJM. Retrieved from nejm.org/doi/full/10.1056/NEJMoa1612674

Nakagawa, K., Garon, E.B., Seto, T., et al. (December 2019). Ramucicromab Plus Erlotinib in Patients With Untreated, EGFR-Mutated, Advanced Non-Small-Cell Lung Cancer (RELAY): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/31591063

Saito, H., Fukuhara, T., Furuya, N., et al. (May 2019). Erlotinib Plus Bevacizumab Versus Erlotinib Alone in Patients With EGFR-Positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/30975627

Holleman, M.S., van Tinteren, H., Groen, H.J., et al. (2019, Feb. 20). First-Line Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Network Meta-Analysis. Retrieved from ncbi.nlm.nih.gov/pubmed/30863108 58

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Peters, S., Camidge, R., Shaw, A.T., et al. (2019, Dec. 26). Alectinib Versus Crizotinib in Untreated ALKPositive Non-Small-Cell Lung Cancer: NEJM. Retrieved from [nejm.org/doi/full/10.1056/NEJMoa1704795](https://doi.org/10.1056/NEJMoa1704795)

Hida, T., Nokihara, H., Kondo, M., et al. (2017, July 1). Alectinib Versus Crizotinib in Patients With ALKPositive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Randomised Phase 3 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/28501140](https://pubmed.ncbi.nlm.nih.gov/28501140)

Camidge, D.R., Kim, H.R., Ahn, M.-J., et al. (2018, Nov. 22). Brigatinib Versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer: NEJM. Retrieved from [nejm.org/doi/full/10.1056/NEJMoa1810171](https://doi.org/10.1056/NEJMoa1810171)

Soria, J.-C., Tan, D.S.W., Chiari, R., et al. (2017, March 4). First-Line Ceritinib Versus Platinum-Based Chemotherapy in Advanced ALK-Rearranged Non-Small-Cell Lung Cancer (ASCEND-4): A Randomised, Open-Label, Phase 3 Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/28126333](https://pubmed.ncbi.nlm.nih.gov/28126333)

Solomon, B.J., Mok, T., Kim, D.-W., et al. (2014, Dec. 4). First-Line Crizotinib Versus Chemotherapy in ALK-Positive Lung Cancer: NEJM. Retrieved from [nejm.org/doi/full/10.1056/NEJMoa1408440](https://doi.org/10.1056/NEJMoa1408440)

Solomon, B.J., Besse, B., Bauer, T.M., et al. (December 2018). Lorlatinib in Patients With ALK-Positive Non-Small-Cell Lung Cancer: Results From a Global Phase 2 Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/30413378](https://pubmed.ncbi.nlm.nih.gov/30413378)

Shaw, A.T., Gandhi, L., Gadgeel, S., et al. (February 2016). Alectinib in ALK-Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/26708155](https://pubmed.ncbi.nlm.nih.gov/26708155)

Ou, S.-H.I., Ahn, J.S., De Petris, L., et al. (2016, March 1). Alectinib in Crizotinib-Refractory ALKRearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Retrieved from [ncbi.nlm.nih.gov/pubmed/26598747](https://pubmed.ncbi.nlm.nih.gov/26598747)

Kim, D.-W., Tiseo, M., Ahn, M.-J., et al. (2017, Aug. 1). Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/28475456](https://pubmed.ncbi.nlm.nih.gov/28475456)

Shaw, A.T., Kim, T.M., Crinò, L. (July 2017). Ceritinib Versus Chemotherapy in Patients With ALKRearranged Non-Small-Cell Lung Cancer Previously Given Chemotherapy and Crizotinib (ASCEND-5): A Randomised, Controlled, Open-Label, Phase 3 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/28602779](https://pubmed.ncbi.nlm.nih.gov/28602779)

Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2016, Nov. 10). Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer: NEJM. Retrieved from [nejm.org/doi/full/10.1056/NEJMoa1606774](https://doi.org/10.1056/NEJMoa1606774)

Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2019, Jan. 8). Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Retrieved from [ascopubs.org/doi/10.1200/JCO.18.00149](https://doi.org/10.1200/JCO.18.00149)

Mok, T.S.K., Wu, Y.-L., Kudaba, I., et al. (2019, May 4). Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Retrieved from [ncbi.nlm.nih.gov/pubmed/30955977](https://pubmed.ncbi.nlm.nih.gov/30955977)

Paz-Ares, L., Luft, A., Vicente, D., et al. (2018, Nov. 22). Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/30280635](https://pubmed.ncbi.nlm.nih.gov/30280635)

Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., et al. (2019, Nov. 21). Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/31562796](https://pubmed.ncbi.nlm.nih.gov/31562796)

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., et al. (2018, May 31). Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. Retrieved from [ncbi.nlm.nih.gov/pubmed/29658856](https://pubmed.ncbi.nlm.nih.gov/29658856) 116. Gadgeel, S.M., Garassino, M.C.,
Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Esteban, E., et al. (2019, May 20). KEYNOTE-189: Updated OS and Progression After the Next Line of Therapy (PFS2) With Pembrolizumab (Pembro) Plus Chemo With Pemetrexed and Platinum vs. Placebo Plus Chemo for Metastatic Nonsquamous NSCLC. Retrieved from ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9013

Langer, C.J., Gadgeel, S.M., Borghaei, H., et al. (November 2016). Carboplatin and Pemetrexed With or Without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study. Retrieved from ncbi.nlm.nih.gov/pubmed/27745820

Borghaei, H., Langer, C.J., Gadgeel, S., et al. (January 2019). 24-Month Overall Survival From KEYNOTE021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/30138764

Socinski, M.A., Jotte, R.M., Cappuzzo, F., et al. (2018, June 14). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. Retrieved from ncbi.nlm.nih.gov/pubmed/29863955 120. Socinski, M.A., Jotte, R.M., Capuzzo, F., et al. (2019, May 26). IMpower150: Analysis of Efficacy in Patients (pts) With Liver Metastases (mets). Retrieved from ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9012

West, H., McCleod, M., Hussein, M., et al. (July 2019). Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared With Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/31122901

Sandler, A., Gray, R., Perry, M.C., et al. (2006, Dec. 14). Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/17167137

Patel, J.D., Socinski, M.A., Garon, E.B., et al. (2013, Dec. 1). PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/24145346

Ramalingam, S.S., Dahlberg, S.E., Belani, C.P., et al. (2019, Sept. 10). Pemetrexed, Bevacizumab, or the Combination as Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOGACRIN 5508. Retrieved from ncbi.nlm.nih.gov/pubmed/31361535

Barlesi, F., Scherpereel, A., Rittmeyer, A., et al. (2013, Aug. 20). Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, 60 Cisplatin and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089). Retrieved from ncbi.nlm.nih.gov/pubmed/23835708

Barlesi, F., Scherpereel, A., Gorbunova, V., et al. (May 2014). Maintenance Bevacizumab-Pemetrexed After First-Line Cisplatin-Pemetrexed-Bevacizumab for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Updated Survival Analysis of the AVAPERL (MO22089) Randomized Phase III Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/24585722

Socinski, M.A., Bondarenko, I., Karaseva, N.A., et al. (2012, June 10). Weekly Nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/22547591

Fossella, F., Pereira, J.R., von Pawel, J., et al. (2003, Aug. 15). Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group. Retrieved from ncbi.nlm.nih.gov/pubmed/12837811

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Fracchi, G., Comella, P., Panza, N., et al. (October 1998). Carboplatin-Oral Etoposide Personalized Dosing in Elderly Non-Small Cell Lung Cancer Patients. Gruppo Oncologico Cooperativo Sud-Italia. Retrieved from ncbi.nlm.nih.gov/pubmed/9893657

Danson, S., Middleton, M.R., O'Byrne, K.J., et al. (2003, Aug. 1). Phase III Trial of Gemcitabine and Carboplatin Versus Mitomycin, Ifosfamide and Cisplatin or Mitomycin, Vinblastine and Cisplatin in Patients With Advanced Non-Small Cell Lung Carcinoma. Retrieved from ncbi.nlm.nih.gov/pubmed/12879472

Ohe, Y., Ohashi, Y., Kubota, K., et al. (February 2007). Randomized Phase III Study of Cisplatin Plus Irinotecan Versus Carboplatin Plus Paclitaxel, Cisplatin Plus Gemcitabine, and Cisplatin Plus Vinorelbine for Advanced Non-Small-Cell Lung Cancer: Four-Arm Cooperative Study in Japan. Retrieved from ncbi.nlm.nih.gov/pubmed/17079694

Belani, C.P., Lee, J.S., Socinski, M.A., et al. (July 2005). Randomized Phase III Trial Comparing CisplatinEtoposide to Carboplatin-Paclitaxel in Advanced or Metastatic Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/15860487

Schiller, J.H., Harrington, D., Belani, C.P., et al. (2002, Jan. 10). Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/11784875

Zukin, M., Barrios, C.H., Pereira, J.R., et al. (2013, Aug. 10). Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2. Retrieved from ascopubs.org/doi/full/10.1200/JCO.2012.48.1911?rss=1

Scagliotti, G.V., Kortsik, C., Dark, G.G., et al. (2005, Jan. 15). Pemetrexed Combined With Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial. Retrieved from ncbi.nlm.nih.gov/pubmed/15701857

Cardenal, F., López-Cabrerizo, M.P., Antón, A., et al. (January 1999). Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic NonSmall-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/10458212

Scagliotti, G.V., Parikh, P., von Pawel, J., et al. (2008, July 20). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage NonSmall-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/18506025

Smit, E.F., van Meerbeeck, J.P.A.M., Lianes, P., et al. (2003, Nov. 1). Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. Retrieved from ncbi.nlm.nih.gov/pubmed/14581415

Pujol, J.-L., Breton, J.-L., Gervais, R., et al. (April 2005). Gemcitabine-Docetaxel Versus CisplatinVinorelbine in Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase III Study Addressing the Case for Cisplatin. Retrieved from ncbi.nlm.nih.gov/pubmed/15741225

Tan, E.H., Szczesna, A., Krzakowski, M., et al. (August 2005). Randomized Study of Vinorelbine — Gemcitabine Versus Vinorelbine — Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/16022917

Green, M.R., Manikhas, G.M., Orlov, S., et al. (August 2006). Abraxane, a Novel Cremophor-Free, Albumin-Bound Particle Form of Paclitaxel for the Treatment of Advanced Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/16740598

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Hanna, N., Shepherd, F.A., Fossella, F.V., et al. (2004, May 1). Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. Retrieved from ncbi.nlm.nih.gov/pubmed/15117980

Zatloukal, P., Kanitz, E., Magyar, P., et al. (December 1998). Gemcitabine in Locally Advanced and Metastatic Non-Small-Cell Lung Cancer: The Central European Phase II Study. Retrieved from ncbi.nlm.nih.gov/pubmed/10048477 144.

Ceresoli, G.L., Gregorc, V., Cordio, S., et al. (May 2004). Phase II Study of Weekly Paclitaxel as Second-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. Retrieved from ncbi.nlm.nih.gov/pubmed/15084388

Lilenbaum, R.C., Herndon, J.E., List, M.A., et al. (2005, Jan. 1). Single-Agent Versus Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The Cancer and Leukemia Group B (Study 9730). Retrieved from ncbi.nlm.nih.gov/pubmed/15625373

Gray, J.E., Villegas, A., Daniel, D., et al. Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-Update From PACIFIC. *J Thorac Oncol.* 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14. PMID: 31622733; PMCID: PMC7244187

Wu, Y.-L., Tsuboi, M., He, J., et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med* 2020;383:1711-1723 148. Herbst, R.S., Giaccone, G., de Marinis, F., et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients With NSCLC. *N Engl J Med.* 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. PMID: 32997907

Sezer, A., Kilickap, S., Gümüş, M., et al. Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of at Least 50%: A Multicentre, Open-Label, Global, Phase 3, 62 Randomised, Controlled Trial. *Lancet.* 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. PMID: 33581821

Paz-Ares, L., Ciuleanu, T.E., Cobo, M., et al. First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. *Lancet Oncol.* 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Erratum in: *Lancet Oncol.* 2021 Mar;22(3):e92. PMID: 33476593

Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. *J Clin Oncol.* 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9. PMID: 32150489

Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50. *J Clin Oncol.* 2021 Apr 19;JCO2100174. doi: 10.1200/JCO.21.00174. Epub ahead of print. PMID: 33872070

Ramalingam, S.S., Ciuleanu, T.E., Pluzanski, A., et al. Nivolumab + Ipilimumab Versus Platinum-Doublet Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Three-Year Update From CheckMate 227 Part 1. 2020 ASCO Virtual Scientific Program. 10.1200/JCO.2020.38.15_suppl.9500. *J Clin Oncol* 38: 2020 (suppl; abstr 9500)

Shaw, A.T., Bauer, T.M., de Marinis, F., et al.; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. *N Engl J Med.* 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. PMID: 33207094

Park, K., Haura, E.B., Leighl, N.B., et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *J Clin Oncol.* 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2. PMID: 34339292; PMCID: PMC8791812.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Ramalingam, S.S., Zhou, C., Kim, T.M., et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase ⅓ study. Doi: 10.1200/JCO.2021.39.15_suppl.9014 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 9014-9014.

Skoulidis, F., Li B.T., Dy G.K., et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4. PMID: 34096690.

Felip, E., Altorki, N., Zhou, C., et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357.

Castro, G.D., Kudaba, I., Wu, Y., et al. 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer. Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.363

Jassem, J., de Marinis, F., Giaccone, G., et al. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1- Selected NSCLC. J Thorac Oncol. 2021 Nov;16(11):1872-1882. doi: 10.1016/j.jtho.2021.06.019. Epub 2021 Jul 12. PMID: 34265434. 63 161. Paz-Ares, L.G., Ciuleanu, T.E., Lee, J.S., et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. J Clin Oncol. 2021. DOI: 10.1200/JCO.2021.39.15_suppl.9016 Journal of Clinical Oncology 39, no. 15_suppl 162. Gray, J., Rodrigues-Abreu, D., Powell, S.F., et al. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189. 2021. Journal of Thoracic Oncology. DOI: https://doi.org/10.1016/j.jtho.2021.01.141_suppl.S224; 16;3

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.